Annexon Inc (ANNX) Stock Price, Quote & News

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also devel...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 822 5500

Fax: 650 636 9773

Website: www.annexonbio.com

Address:

1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States

Thomas105 Aug. 5 at 8:11 AM

$ANNX maximum ask looks promising

0 · Reply

Sly15 Aug. 4 at 8:04 PM

$ANNX Forward label study results should be close to being done now. Could announce results in earnings call and I expect them to be very positive. 1502 information could be released as we are getting past mid 2025 now, and positive updated on BLA submission. Could be a very strong earnings release with a lot of good information, hopefully next week.

1 · Reply

TeeMan123 Aug. 4 at 4:15 PM

$ANNX longer the delay the better imo.. must mean btd is on the table. If it was not able to file dynamic it would have been a faster response

1 · Reply

Sly15 Aug. 2 at 2:29 PM

$ANNX to add to my point below we are not talking about ema submission in Europe. This is relevant because Europe has twice the amount of cases as U.S. does for gbs. Best optimistic scenario on when this could be ready in Europe is end of 2026 at this point. Some sales from the U.S. maybe back half of 2026, best case an extra quarter. Seems questionable to me they won’t need to raise money in 2026. Just don’t reasonable see them generating enough revenue soon enough to make a difference in preventing that. It will make a little difference potentially in how much they need to raise though.

0 · Reply

Sly15 Aug. 1 at 8:09 PM

$ANNX looks like we will have to wait until earnings release to hear about tanruprubart bla information. Hopefully we will hear they have submitted the application, or will have it submitted within a couple weeks. Earnings release expected around aug 10. So two more weeks, give or take a week. Stock is consolidating in price right now awaiting news before making any big move. I have doubts on them Persuing priority review. Either way they will need money as generating sales for the first 4 months earlier likely won’t be enough to offset their costs if they did get a priorty review approved.

2 · Reply

Thomas105 Aug. 1 at 9:27 AM

$ANNX go for 3

0 · Reply

TeeMan123 Jul. 31 at 12:17 PM

$ANNX July 31…. Where’s the bla info???

2 · Reply

Acan1219 Jul. 30 at 5:19 PM

$ANNX Just a matter of time my Bull’s!!💰💰💰 Double Digit’s soon! Imho..💰💰💰

0 · Reply

Thomas105 Jul. 30 at 4:52 PM

$ANNX

0 · Reply

raj3406 Jul. 30 at 4:52 PM

$ANNX What's happening today?

2 · Reply

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 14, 2025, 12:47 PM EDT - 22 days ago

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Jun 18, 2025, 4:05 PM EDT - 6 weeks ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

May 29, 2025, 4:05 PM EDT - 2 months ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 4:05 PM EDT - 2 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 16, 2025, 4:05 PM EDT - 2 months ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2025, 8:00 AM EDT - 3 months ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 9, 2025, 5:00 PM EDT - 3 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 7, 2025, 8:00 AM EDT - 3 months ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Apr 16, 2025, 4:05 PM EDT - 3 months ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 7:12 AM EDT - 4 months ago

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Apr 8, 2025, 4:05 PM EDT - 4 months ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 4 months ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Mar 3, 2025, 8:00 AM EST - 5 months ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Feb 26, 2025, 4:05 PM EST - 5 months ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:30 AM EST - 6 months ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Jan 7, 2025, 8:00 AM EST - 7 months ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:30 AM EST - 8 months ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Nov 14, 2024, 8:00 AM EST - 9 months ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 13, 2024, 4:05 PM EST - 9 months ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Oct 21, 2024, 8:00 PM EDT - 10 months ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 3, 2024, 1:20 AM EDT - 10 months ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Aug 17, 2024, 9:28 AM EDT - 1 year ago

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Jul 11, 2024, 6:09 PM EDT - 1 year ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jun 25, 2024, 5:00 PM EDT - 1 year ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 5, 2024, 11:04 PM EDT - 1 year ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 4, 2024, 5:06 PM EDT - 1 year ago

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 2:07 PM EDT - 1 year ago

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 4, 2024, 7:11 AM EDT - 1 year ago

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

May 13, 2024, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 9, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 7, 2024, 12:30 PM EDT - 1 year ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 1, 2024, 8:00 AM EDT - 1 year ago

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 4:05 PM EDT - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Feb 27, 2024, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

Feb 21, 2024, 8:00 AM EST - 1 year ago

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach

Jan 7, 2024, 8:00 PM EST - 1 year ago

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Dec 27, 2023, 6:30 AM EST - 1 year ago

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 23, 2023, 12:00 PM EST - 1 year ago

Annexon: ANX007 Advances Forward With Stellar Endpoint

Dec 20, 2023, 5:27 PM EST - 1 year ago

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

Dec 20, 2023, 5:10 PM EST - 1 year ago

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Dec 20, 2023, 5:08 PM EST - 1 year ago

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Nov 22, 2023, 4:01 PM EST - 1 year ago

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 6:30 AM EST - 1 year ago

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

Nov 9, 2023, 6:30 AM EST - 1 year ago

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

Oct 24, 2023, 6:30 AM EDT - 1 year ago

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

Oct 10, 2023, 6:30 AM EDT - 1 year ago

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

Sep 19, 2023, 6:30 AM EDT - 2 years ago

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

Thomas105 Aug. 5 at 8:11 AM

$ANNX maximum ask looks promising

0 · Reply

Sly15 Aug. 4 at 8:04 PM

1 · Reply

TeeMan123 Aug. 4 at 4:15 PM

$ANNX longer the delay the better imo.. must mean btd is on the table. If it was not able to file dynamic it would have been a faster response

1 · Reply

Sly15 Aug. 2 at 2:29 PM

0 · Reply

Sly15 Aug. 1 at 8:09 PM

2 · Reply

Thomas105 Aug. 1 at 9:27 AM

$ANNX go for 3

0 · Reply

TeeMan123 Jul. 31 at 12:17 PM

$ANNX July 31…. Where’s the bla info???

2 · Reply

Acan1219 Jul. 30 at 5:19 PM

$ANNX Just a matter of time my Bull’s!!💰💰💰 Double Digit’s soon! Imho..💰💰💰

0 · Reply

Thomas105 Jul. 30 at 4:52 PM

$ANNX

0 · Reply

raj3406 Jul. 30 at 4:52 PM

$ANNX What's happening today?

2 · Reply

NVDAMillionaire Jul. 29 at 11:46 PM

$ANNX Really good write-up that perfectly summarizes ANNX's present situation. So if you want to bring your ANNX knowledge up to date or just discover ANNX, this is required reading. https://beyondspx.com/article/annexon-unlocking-the-classical-complement-pathway-with-key-catalysts-on-the-horizon-annx

0 · Reply

Bioinvest2020 Jul. 29 at 3:59 PM

$ANNX While I am still hoping for a news release this week and a substantial stock re-rating, one possibility is that $ANNX applied for BTD shortly after the pre-BLA meeting (with FDA encouragement) and is waiting to bundle the news together. That would potentially push the announcement out another week or two given that FDA typically responds within 30-40 days of BTD requests.

2 · Reply

Sly15 Jul. 25 at 3:24 PM

$ANNX Looking more like we are going to have to wait until 2nd quarter earnings release before hearing anything on Tanruprubart. Little annoyed at that one. 3-4 more weeks of waiting.

2 · Reply

Lightening_strikes Jul. 24 at 4:14 PM

$ANNX I think need to see a path for getting cash. Runway is shorter and shorter

0 · Reply

TeeMan123 Jul. 24 at 1:38 PM

$ANNX I see you Dr Love.. greasing the wheels before you make this stock go parabolic with the gbs fda outcome!!

1 · Reply

G101SPM Jul. 24 at 12:18 PM

$ANNX $3.38 bid. DAC $3.28 (3.3.25). EXIT $8.00. BRIEF: Anixa Biosciences announces the United States Patent and Trademark Office will issue U.S. Patent Number 12,370,244 on July 29, covering key aspects of the Company's breast cancer vaccine technology (3.38) note: Patent expands immunogenic coverage of a-lactalbumin-based vaccine platform. Technology addresses substantial unmet need in preventive oncology with multi-billion dollar market potential.

0 · Reply

Sly15 Jul. 24 at 11:59 AM

$ANNX Finally some good news with ANX007. Originally expected to complete enrollment end of 2025, then pulled up to end of Q3 2025, now two months early due to high demand. A name for the drug also "Vonaprument". Awesome!!

1 · Reply

BigSqueezeComing Jul. 24 at 11:49 AM

$ANNX pt 3 Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy By Annexon Biosciences | July 24, 2025, 7:00 AM

0 · Reply

G101SPM Jul. 24 at 11:42 AM

#SHOWTIME $ANNX $2.60 bid Hold long position. ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design and Rationale Informed by Outcomes From ARCHER” Presenter: David A. Eichenbaum, MD, FASRS, Retina Specialist, Retina Vitreous Associates of Florida Date/Time: Thursday, July 31 at 2:59 pm Pacific Time (PT)

0 · Reply

G101SPM Jul. 24 at 11:11 AM

$ANNX $2.48 bid. DAC (dollar average cost) (8) $3.44 / last $1.57 (4.9.25). EXIT $15.00. UPDATE: Annexon announces completion of enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (2.48) note: Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures.

0 · Reply

DARKP00L Jul. 24 at 11:06 AM

$ANNX 07:05 on Jul. 24 2025 Annexon Completes Enrollment In Pivotal Phase 3 ARCHER II Trial Of Vonaprument For Dry Age-Related Macular Degeneration With Geographic Atrophy #tradeideas

0 · Reply

Lightening_strikes Jul. 22 at 4:19 PM

$ANNX gravity again

0 · Reply

Market Cap	268.80M
Revenue (ttm)	0.00
Net Income (ttm)	-138.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	249,982
Avg Vol	1,558,332
Day's Range	N/A - N/A
Shares Out	109.71M
Stochastic %K	53%
Beta	1.30
Analysts	Strong Sell
Price Target	$11.60